Spots Global Cancer Trial Database for A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
Official Title: A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (ILLUMINATE-101)
Study ID: NCT03052205
Interventions
Study Description
Brief Summary: This is a Phase 1b study that incorporates dose expansion cohorts to further evaluate promising clinical or biological activity.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Scottsdale Healthcare Hospitals DBA Honor Health, Scottsdale, Arizona, United States
The University of Arizona Cancer Center, Tucson, Arizona, United States
University of California San Francisco (UCSF), San Francisco, California, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
The Cleveland Clinic Foundation, Cleveland, Ohio, United States
St. Luke's Hospital, Easton, Pennsylvania, United States
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
MD Anderson Cancer Center, Houston, Texas, United States
Rambam Medical Center, Haifa, , Israel
Hadassah Medical Center, Jerusalem, , Israel
Rabin Medical Center Beilinson Campus, Petah tikva, , Israel
The Ella Lemelbaum Institute for Immuno-Oncology, Ramat Gan, , Israel
Contact Details
Name: Idera Medical Director
Affiliation: Idera Pharmaceuticals, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
